New Investigational Drug for CF Patients with NTM Infection

Trial Objective

New Investigational Drug for CF Patients with NTM InfectionThis study will determine if a new investigational drug helps treat ongoing nontuberculous mycobacterial (NTM) infection in adults with cystic fibrosis. The medication, Molgramostim Nebulized Solution, is not an antibiotic, but is designed to stimulate an immune response to better fight infection. Participants will nebulize the drug once a day after their full morning routine. Everyone in the trial will get the active drug.


New enrollment for this trial is temporarily paused

Who Can Participate

Adults who are diagnosed with cystic fibrosis and have ongoing mycobacterial infection.

Age: 18+    Gender: Any Gender

Estimated Time Commitment

Study involvement will last for about 18 months.

Participants will nebulize the drug for 48 weeks. There are 19 visits that take 3-4 hours each.

Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Available

Trial Contact

For more information, contact:

Alexandria Leonhardt

Alexandria Leonhardt

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors


Principal Investigators

Request More Information

Due to concerns around COVID-19 and our focus on helping to meet this momentous challenge, we have temporarily paused enrollment for all trials requiring an in-person visit. Please feel free to request additional information about any of the trials we have posted and we will get back to you when enrollment resumes. For more resources and information on COVID-19 please visit our special coronavirus website at